Vanda Salutari, MD

Vanda Salutari, MD, is an oncologist in the Department of Health of Woman and Child at the Catholic University of Sacred Heart, in Rome, Italy.

Articles by Vanda Salutari, MD

Vanda Salutari, MD, Catholic University of the Sacred Heart

Dr Salutari on the Rationale for Evaluating Relacorilant Plus Nab-Paclitaxel in PARP Inhibitor–Treated PROC

ByVanda Salutari, MD

October 23rd 2025

Vanda Salutari, MD, discusses the rationale for examining relacorilant plus nab-paclitaxel in PARP inhibitor–treated platinum-resistant ovarian cancer.

Vanda Salutari, MD

Articles by Vanda Salutari, MD

Dr Salutari on the Rationale for Evaluating Relacorilant Plus Nab-Paclitaxel in PARP Inhibitor–Treated PROC

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD

Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer

Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma